+++++++++++++++++++++++++ Unitract Ltd ("Unitract" ASX code: UNI) today announced the signing of a contract with Carpe DM Inc, ("CDM") of the United States to assist Unitract Ltd penetrate the world's largest syringe market.
Unitract Ltd has engaged CDM to be its exclusive representative in the United States to arrange direct sales, strategic alliances, partnerships, manufacturing agreements, royalty agreements and any other agreements that will result in sales, revenue and gross receipts outside the harm reduction industry.
CDM and its President Mr Fine have had significant experience in pharmaceutical, consumer products, media and investor relations, manufacturing, financial services, Internet systems and accounting.
Mr David Riekle, Chairman of Unitract Ltd said Mr Fine and CDM would play a key role in Unitract fulfilling its objectives of gaining product approval and acquiring market share within the United States.
"Mr Edward Fine and Carpe DM Inc have the corporate profile and expertise Unitract Ltd requires to help it penetrate target markets within the United States," Mr Riekle said.
During his forty-year career, Mr Fine has served as the CEO of Dyna-Lease Corporation, Newtron Pharmaceuticals, Inc and Biopharmaceuticals, Inc, as well as holding management and executive positions with Reliance Group and Plizer Inc.
Unitract Ltd is committed to helping reduce the global transmission of blood borne diseases caused by accidental needle stick injuries and the sharing of unsafe or used syringes via the production and supply of retractable syringe technology.
